Cash, Krugler & Fredericks

Gadolinium Lawsuits

gadolinium MRI

Atlanta Attorneys Cash, Krugler & Fredericks, are investigating and pursuing claims on behalf of patients who have been injured by MRI contrast agents containing the metal gadolinium. Our firm has a network of relationships around the country and we can pursue your claim now. All cases are handled on a contingency basis, so there are no up-front costs to our clients.

In June 2006, the U.S. Food & Drug Administration (FDA) first notified healthcare professionals and the public about a possible link between the use of gadolinium-based contrast agents in patients with renal problems and a condition known as nephrogenic systemic fibrosis (NSF). Since that time, the FDA has received hundreds of reports of patients who have developed NSF after being exposed to gadolinium-based contrast agents.

If you have been diagnosed with or are suffering from symptoms of NSF, you may have a claim against the manufacturers of these contrast agents. On September 9, 2010, the FDA strengthened the warnings on all gadolinium MRI Dyes by requiring new “black box” warnings on labels regarding the association of gadolinium with NSF. In addition, the FDA has required that three of the dyes – Bayer Healthcare’s Magenvist, GE Healthcare’s Omniscan and Covidien’s Optimark – be described as inappoproriate for use among patients with acute kidney injury or chronic severe kidney disease. Additional screening and testing will also be emphasized before the use of gadolinium-based MRI agents in patients.

For additional information, please free to use our Online Consultation Formemail usor call our Atlanta Attorneys at (404) 659-1710 to discuss your case.

Cash, Krugler & Fredericks., © 2017. All rights reserved.